Ocugen Analyst Ratings
Ocugen Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/31/2023 | 350.45% | Cantor Fitzgerald | $2.5 → $2 | Maintains | Overweight |
| 08/23/2023 | 1026.13% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/08/2023 | 800.9% | Chardan Capital | $3.5 → $4 | Maintains | Buy |
| 04/17/2023 | 1026.13% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 04/14/2023 | 688.29% | Chardan Capital | → $3.5 | Maintains | Buy |
| 03/01/2023 | 688.29% | Chardan Capital | → $3.5 | Upgrades | Neutral → Buy |
| 03/01/2023 | 575.68% | Mizuho | $5 → $3 | Maintains | Buy |
| 03/01/2023 | 1026.13% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 08/23/2022 | 1026.13% | Mizuho | → $5 | Initiates Coverage On | → Buy |
| 08/15/2022 | 1251.35% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 06/15/2022 | 1701.8% | Roth Capital | → $8 | Reinstates | → Buy |
| 06/02/2022 | 913.51% | Cantor Fitzgerald | → $4.5 | Initiates Coverage On | → Overweight |
| 05/12/2022 | 1476.58% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 02/28/2022 | 1701.8% | HC Wainwright & Co. | $10 → $8 | Maintains | Buy |
| 06/11/2021 | 1251.35% | Roth Capital | $10 → $6 | Downgrades | Buy → Neutral |
| 06/11/2021 | 2152.25% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 05/07/2021 | 2377.48% | Cantor Fitzgerald | $15 → $11 | Downgrades | Overweight → Neutral |
| 03/03/2021 | 3278.38% | Cantor Fitzgerald | $4 → $15 | Maintains | Overweight |
| 02/09/2021 | 2827.93% | Chardan Capital | $0.7 → $13 | Downgrades | Buy → Neutral |
| 02/04/2021 | 913.51% | HC Wainwright & Co. | → $4.5 | Upgrades | Neutral → Buy |
| 11/17/2020 | 125.23% | Roth Capital | → $1 | Initiates Coverage On | → Buy |
| 10/09/2020 | 125.23% | Cantor Fitzgerald | → $1 | Initiates Coverage On | → Overweight |
| 06/03/2020 | 57.66% | Chardan Capital | $2 → $0.7 | Maintains | Buy |
| 06/01/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 12/20/2019 | — | HC Wainwright & Co. | Initiates Coverage On | → Buy | |
| 11/27/2019 | 350.45% | Chardan Capital | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/31/2023 | 350.45% | 坎托·菲茨杰拉德 | 2.5 美元 → 2 美元 | 维持 | 超重 |
| 08/23/2023 | 1026.13% | HC Wainwright & Co. | → 5 美元 | 重申 | 购买 → 购买 |
| 05/08/2023 | 800.9% | 查丹资本 | 3.5 美元 → 4 美元 | 维持 | 购买 |
| 04/17/2023 | 1026.13% | HC Wainwright & Co. | → 5 美元 | 重申 | → 购买 |
| 04/14/2023 | 688.29% | 查丹资本 | → 3.5 美元 | 维持 | 购买 |
| 03/01/2023 | 688.29% | 查丹资本 | → 3.5 美元 | 升级 | 中性 → 买入 |
| 03/01/2023 | 575.68% | 瑞穗市 | 5 美元 → 3 美元 | 维持 | 购买 |
| 03/01/2023 | 1026.13% | HC Wainwright & Co. | 6 美元 → 5 美元 | 重申 | → 购买 |
| 2022 年 8 月 23 日 | 1026.13% | 瑞穗市 | → 5 美元 | 启动覆盖范围开启 | → 购买 |
| 08/15/2022 | 1251.35% | HC Wainwright & Co. | 7 美元 → 6 美元 | 维持 | 购买 |
| 06/15/2022 | 1701.8% | 罗斯资本 | → 8 美元 | 恢复 | → 购买 |
| 06/02/2022 | 913.51% | 坎托·菲茨杰拉德 | → 4.5 美元 | 启动覆盖范围开启 | → 超重 |
| 05/12/2022 | 1476.58% | HC Wainwright & Co. | 8 美元 → 7 美元 | 维持 | 购买 |
| 02/28/2022 | 1701.8% | HC Wainwright & Co. | 10 美元 → 8 美元 | 维持 | 购买 |
| 06/11/2021 | 1251.35% | 罗斯资本 | 10 美元 → 6 美元 | 降级 | 买入 → 中性 |
| 06/11/2021 | 2152.25% | HC Wainwright & Co. | 12 美元 → 10 美元 | 维持 | 购买 |
| 05/07/2021 | 2377.48% | 坎托·菲茨杰拉德 | 15 美元 → 11 美元 | 降级 | 超重 → 中性 |
| 03/03/2021 | 3278.38% | 坎托·菲茨杰拉德 | 4 美元 → 15 美元 | 维持 | 超重 |
| 02/09/2021 | 2827.93% | 查丹资本 | 0.7 美元 → 13 美元 | 降级 | 买入 → 中性 |
| 02/04/2021 | 913.51% | HC Wainwright & Co. | → 4.5 美元 | 升级 | 中性 → 买入 |
| 2020 年 11 月 17 日 | 125.23% | 罗斯资本 | → 1 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 9 月 10 日 | 125.23% | 坎托·菲茨杰拉德 | → 1 美元 | 启动覆盖范围开启 | → 超重 |
| 06/03/2020 | 57.66% | 查丹资本 | $2 → 0.7 美元 | 维持 | 购买 |
| 06/01/2020 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
| 12/20/2019 | — | HC Wainwright & Co. | 启动覆盖范围开启 | → 购买 | |
| 11/27/2019 | 350.45% | 查丹资本 | → 2 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Ocugen (OCGN)?
Ocugen（OCGN）的目标价格是多少？
The latest price target for Ocugen (NASDAQ: OCGN) was reported by Cantor Fitzgerald on August 31, 2023. The analyst firm set a price target for $2.00 expecting OCGN to rise to within 12 months (a possible 350.45% upside). 8 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年8月31日公布了奥库根（纳斯达克股票代码：OCGN）的最新目标股价。该分析公司将目标股价设定为2.00美元，预计OCGN将在12个月内上涨至2.00美元（可能上涨350.45％）。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Ocugen (OCGN)?
Ocugen (OCGN) 的最新分析师评级是多少？
The latest analyst rating for Ocugen (NASDAQ: OCGN) was provided by Cantor Fitzgerald, and Ocugen maintained their overweight rating.
奥库根（纳斯达克股票代码：OCGN）的最新分析师评级由坎托·菲茨杰拉德提供，奥库根维持增持评级。
When is the next analyst rating going to be posted or updated for Ocugen (OCGN)?
Ocugen（OCGN）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocugen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocugen was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Ocugen的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Ocugen的最后一次评级是在2023年8月31日提交的，因此您应该预计下一个评级将在2024年8月31日左右公布。
Is the Analyst Rating Ocugen (OCGN) correct?
分析师评级 Ocugen (OCGN) 是否正确？
While ratings are subjective and will change, the latest Ocugen (OCGN) rating was a maintained with a price target of $2.50 to $2.00. The current price Ocugen (OCGN) is trading at is $0.44, which is out of the analyst's predicted range.
尽管评级是主观的，并将发生变化，但最新的Ocugen（OCGN）评级维持不变，目标股价为2.50美元至2.00美元。Ocugen（OCGN）目前的交易价格为0.44美元，超出了分析师的预测区间。
译文内容由第三方软件翻译。